Synergistic activities of fluconazole and voriconazole with terbinafine against four Candida species determined by checkerboard, time-kill, and etest methods

Antimicrobial Agents and Chemotherapy

Volumn 49, Issue 4, 2005, Pages 1593-1596

  Cantón, Emilia ^a   Pemân, Javier ^a   Gobernado, Miguel ^a   Viudes, Angel ^a   Espinel Ingroff, Ana ^b  

^a HOSPITAL UNIVERSITARIO LA FE   (Spain)

^b VIRGINIA COMMONWEALTH UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FLUCONAZOLE; TERBINAFINE; VORICONAZOLE;

ANTIFUNGAL ACTIVITY; ARTICLE; CANDIDA; CANDIDA ALBICANS; CANDIDA GLABRATA; CANDIDA KRUSEI; CANDIDA TROPICALIS; DRUG POTENTIATION; FUNGUS ISOLATION; INTERMETHOD COMPARISON; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PRIORITY JOURNAL; QUALITY CONTROL;

ANTIFUNGAL AGENTS; CANDIDA; DRUG SYNERGISM; FLUCONAZOLE; MICROBIAL SENSITIVITY TESTS; NAPHTHALENES; PYRIMIDINES; TRIAZOLES;

EID: 16244401925     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/AAC.49.4.1593-1596.2005     Document Type: Article

References (19)

1. Afeltra, J., J. F. G. Meis, R. G. Vitale, J. W. Mouton, P. E. Verweij, and the Eurofung Network. 2002. In vitro activities of pentamidine, trimethoprim, and sulfonamides against Aspergillus species. Antimicrob. Agents Chemother. 46:2029-2031.
2. Andes, D., K. Marchillo, T. Stamstad, and R. Conklin. 2003. In vivo pharmacokinetics and pharmacodynamics of a new triazole, voriconazole, in a murine candidiasis model. Antimicrob. Agents Chemother. 47:3165-3169.
3. Balfour, J. A., and D. Faulds. 1992. Terbinafine. A review of its pharmacokinetic properties, and therapeutic potential in superficial mycosis. Drugs 43:259-284.
4. Barchiesi, F., L. Falconi Di Francesco, and G. Scalise. 1997. In vitro activities of terbinafine in combination with fluconazole and itraconazole against isolates of Candida albicans with reduced susceptibility to azoles. Antimicrob. Agents Chemother. 41:1812-1814.
5. Barchiesi, F., L. Falconi Di Francesco, P. Compagnucci, D. Arzeni, A. Giacometti, and G. Scalise. 1998. In-vitro interaction of terbinafine with amphotericin B, fluconazole and itraconazole against clinical isolates of Candida albicans. J. Antimicrob. Chemother. 41:59-65.
6. Barry, A. L., M. A. Pfaller, S. D. Brown, et al. 2000. Quality control limits for broth microdilution susceptibility tests of ten antifungal agents. J. Clin. Microbiol. 38:3457-3459.
7. Cantón, E., J. Pemán, M. Romero, and M. Gobernado. 2004. Utilidad del E-test y sus condiciones de ensayo en el estudio de la interacción de los antifúngicos. Estudio piloto. Rev. Esp. Quimioterap. 17:48-56.
8. Cantón, E., J. Pemán, M. Gobernado, A. Viudes, and A. Espinel-Ingroff. 2004. Killing kinetics patterns of amphotericin B against seven Candida species. Antimicrob. Agents Chemother. 48:2477-2482.
9. Grant, S. M., and S. P. Clissold. 1990. Fluconazole. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in superficial and systemic mycoses. Drugs 39:877-916.
10. Hoffman, H. L., and R. C. Rathbun. 2002. Review of the safety and efficacy of voriconazole. Expert Opin. Investig. Drugs 11:409-429.
11. Kovarik, J. M., E. A. Mueller, H. Zehender, J. Denouel, H. Caplain, and L. Millerioux. 1995. Multiple-dose pharmacokinetics and distribution in tissue of terbinafine and metabolites. Antimicrob. Agents Chemother. 39:2738-2741.
12. National Committee for Clinical Laboratory Standards. 2002. Reference method for broth dilution antifungal susceptibility testing of yeasts. Approved standard, 2nd ed. NCCLS document M27-A2. National Committee for Clinical Laboratory Standards, Wayne, Pa.
13. National Committee for Clinical Laboratory Standards. 2004. Method for antifungal disk diffusion susceptibility testing of yeasts. Approved guideline. NCCLS document M44-A. National Committee for Clinical Laboratory Standards, Wayne, Pa.
14. Perea, S., G. Gonzalez, A. W. Fothergill, D. A. Sutton, and M. G. Rinaldi. 2002. In vitro activities of terbinafine in combination with fluconazole, itraconazole, voriconazole, and posaconazole against clinical isolates of Candida glabrata with decreased susceptibility to azoles. J. Clin. Microbiol. 40:1831-1833.
15. Pina-Vaz, C., F. Sansonetty, A. G. Rodríguez, J. Martinez-De-Oliveira, A. F. Fonseca, and P. A. Mardh. 2000. Antifungal activity of ibuprofen alone and in combination with fluconazole against Candida species. J. Med. Microbiol. 49:831-840.
16. Purkins, L., N. Wood, P. Ghahramani, K. Greenhalgh, M. J. Allen, and D. Kleinermans. 2002. Pharmacokinetics and safety of voriconazole following intravenous- to oral-dose escalation regimens. Antimicrob. Agents Chemother. 46:2546-2553.
17. Silling, G. 2002. Fluconazole: optimized antifungal therapy based on pharmacokinetics. Mycoses 45(Suppl. 3):39-41.
18. Sorensen, K. N., R. A. Sobel, K. V. Clemons, L. Calderon, K. J. Howell, P. R. Irani, D. Pappagianis, P. L. Williams, and D. A. Stevens. 2000. Comparative efficacies of terbinafine and fluconazole in treatment of experimental coccidioidal meningitis in a rabbit model. Antimicrob. Agents Chemother. 44:3087-3091.
19. Weig, M., and F. M. Muller. 2001. Synergism of voriconazole and terbinafine against Candida albicans isolates from human immunodeficiency virus-infected patients with oropharyngeal candidiasis. Antimicrob. Agents Chemother. 45:966-968.